MEI Pharma Makes Strategic $100 Million Move into Litecoin
-
最新报道：Mei Pharma, a biopharmaceutical company, has adopted Litecoin (LTC) as part of its treasury strategy, allocating $6 million to the cryptocurrency. The firm plans to hold LTC as a long-term investment, citing its potential for growth and utility in payments. CEO Daniel Gold emphasized Litecoin’s stability and adoption as key factors in the decision. The move follows similar treasury allocations by companies like MicroStrategy and Tesla, signaling growing corporate interest in crypto assets. Litecoin’s founder, Charlie Lee, welcomed the announcement, highlighting its validation of LTC’s value proposition. The decision reflects broader institutional confidence in cryptocurrencies as reserve assets.
下一篇
BNB Drops Below 790 USDT with a Narrowed 3.88% Increase in 24 Hours
- On Jul 23, 2025, 10:01 AM(UTC). According to Binance Market Data, BNB has dropped below 79...
24小时热点
热点专题
407297